MedTrace Logo

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma

NCT04133636 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2026-04-13

No results posted yet for this study

Summary

The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.

Conditions

Interventions

DRUG

JNJ-68284528

Participants in Cohorts A,B,C, D, E, F, G, and H will receive JNJ-68284528 intravenously.

DRUG

Lenalidomide

Some participants in Cohort D and all participants in Cohorts E, G, and H will also receive lenalidomide capsules orally.

DRUG

Daratumumab

Participants in Cohorts E, G, and H will also receive daratumumab subcutaneous (SC) injection.

DRUG

Bortezomib

Participants in Cohorts E and H will also receive bortezomib subcutaneously.

DRUG

Dexamethasone

Participants in Cohorts E, G, and H will also receive dexamethasone orally or intravenously.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-07
Primary Completion
2026-08-04
Completion
2029-09-03
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • France
  • Germany
  • Israel
  • Netherlands
  • Saudi Arabia
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04133636 on ClinicalTrials.gov